Regatta Capital Group LLC Makes New Investment in Gilead Sciences, Inc. $GILD

Regatta Capital Group LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,062 shares of the biopharmaceutical company’s stock, valued at approximately $451,000.

Several other hedge funds also recently made changes to their positions in GILD. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. GoalVest Advisory LLC lifted its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth $27,000. Putney Financial Group LLC increased its position in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. Finally, Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the second quarter valued at about $30,000. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. HSBC increased their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Wells Fargo & Company upped their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Scotiabank started coverage on Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $131.54.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer owned 153,503 shares in the company, valued at approximately $18,727,366. This trade represents a 1.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 126,257 shares of company stock valued at $15,606,892 over the last three months. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $124.70 on Monday. The firm’s fifty day moving average price is $122.95 and its two-hundred day moving average price is $116.71. The stock has a market cap of $154.71 billion, a PE ratio of 19.33, a PEG ratio of 0.69 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the business posted $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.